



Count on Pr TREANDA®

TREANDA (bendamustine hydrochloride for injection) is indicated for treatment of patients with relapsed indolent B-cell non-Hodgkin lymphoma (NHL) who did not respond to or progressed during or shortly following treatment with a rituximab regimen.

iNHL

**TREANDA for the treatment
of relapsed indolent B-cell
non-Hodgkin lymphoma¹**

For more information: Please consult the product monograph at https://pdf.hres.ca/dpd_pm/00043152.PDF for contraindications, warnings, precautions, adverse reactions, interactions, dosing, and conditions for clinical use. The product monograph is also available by calling Teva Canada Innovation at 1-833-662-5644.

Reference: 1. TREANDA® Product Monograph. Teva Canada Limited. January 10, 2018.

teva | Oncology | Canada

Brands. Generics. Biosimilars.

Pr TREANDA®
(bendamustine HCl)
for Injection

TREANDA is a registered trademark of Cephalon, Inc., an affiliate of Teva Canada Innovation G.P. – S.E.N.C., and is used under licence.
© 2019 Teva Canada Innovation G.P. – S.E.N.C. Montreal, Quebec, H2Z 1S8 TRE18-PTH06E

04/2021